Okay, I'll be very brief.
The issue around industry-funded groups is that in general—and this is a generalization—they tend to emphasize faster access to new products and they under-emphasize safety concerns. Almost always they are talking about needing access. That seems partly to be a defence of a patient group that might need access to that drug, but it also reflects what is very much in the pharmaceutical company's interests.